UNASSIGNED: Forty participants experiencing sleep discomfort were enrolled in a double-blind randomized controlled trial, wherein they received LTC-022 or a placebo orally for 8 weeks. The effects of treatment on sleep quality were assessed using the Pittsburgh Sleep Quality Index and Insomnia Severity Index. To comprehensively evaluate changes in sleep patterns, various parameters were evaluated, including the time in bed (TIB), total sleep time (TST), sleep onset latency (SOL), sleep efficiency (SE), wake after sleep onset (WASO) counts, and bedtime. These parameters were derived from daily sleep logs recorded over the 8-week study period, categorized into weekdays and weekends. Stool samples were analyzed for microbiome composition. The V4 region of bacterial 16S rRNA genes was amplified using specific primers (515F and 806R) and targeted for analysis. Microbial diversity, including operational taxonomic units, the Shannon and Chao indices, the Firmicutes/Bacteroidetes (F/B) ratio, and the variety of bacterial taxa, was assessed.
UNASSIGNED: No significant differences were observed in sleep quality and insomnia scale characteristics between the two groups. In-depth analysis using sleep diaries showed that WASO counts after 8 weeks and bedtime after 4 weeks showed significant differences between the LTC-022 and control groups. In the LTC-022 group, significant differences were observed in the increase in TST, decrease in SOL, increase in SE, decrease in WASO counts, and earlier bedtime. Microbiome analysis revealed that the abundance of the genera Blautia and Ruminococcus increased in fecal samples from the LTC-022 group.
UNASSIGNED: These results suggest that continuous LTC-022 intake has a beneficial effect on maintaining sleep duration and an appropriate bedtime. Additionally, changes in the gut microbiota may be linked to changes in sleep patterns resulting from the consumption of Lactium and L-theanine.
UNASSIGNED: https://cris.nih.go.kr/cris/search/detailSearch.do/22841, KCT0007750.
40名出现睡眠不适的参与者参加了一项双盲随机对照试验,其中他们口服接受LTC-022或安慰剂8周。使用匹兹堡睡眠质量指数和失眠严重程度指数评估治疗对睡眠质量的影响。为了全面评估睡眠模式的变化,对各种参数进行了评估,包括在床上的时间(TIB),总睡眠时间(TST),睡眠发作潜伏期(SOL),睡眠效率(SE),睡眠发作后醒来(WASO)计数,还有就寝时间.这些参数来自8周研究期间记录的每日睡眠日志,分为工作日和周末。分析粪便样品的微生物组组成。使用特异性引物(515F和806R)扩增细菌16SrRNA基因的V4区,并靶向分析。微生物多样性,包括操作分类单位,Shannon和Chao指数,厚壁菌/拟杆菌(F/B)比率,以及各种细菌分类群,被评估。
■两组睡眠质量和失眠量表特征无明显差异。使用睡眠日记的深入分析显示,8周后的WASO计数和4周后的就寝时间在LTC-022和对照组之间显示出显着差异。在LTC-022组中,在TST的增加方面观察到显著差异,SOL减少,SE增加,WASO计数减少,和更早的就寝时间。微生物组分析显示,LTC-022组的粪便样品中布劳特氏菌和Ruminococus属的丰度增加。
■这些结果表明,连续摄入LTC-022对保持睡眠时间和适当的就寝时间具有有益作用。此外,肠道微生物群的变化可能与因食用Lactium和L-茶氨酸而导致的睡眠模式的变化有关。
■https://cris。nih.走吧。kr/cris/search/detailSearch.做/22841,KCT0007750。